Big lung cancer collaboration has this tiny stock soaring

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 June 10, 2024 | [Read Online]( Big lung cancer collaboration has this tiny stock soaring Today’s big movers inside [Bishop on X]( I [MarketMaster’s]( I 🎯[Bullseye]( *together with Mode Mobile Good day, 360! Just a reminder [Jeff’s Bullseye]( is dropping in 3..2.. (at 9:20AM EST!) — get in there quickly! And don’t forget to join us ALL day in our [#1 Trading Room](. Be the best prepared trader on the Street! FOCUS LIST🔎 GERN - Up over 38% in the pre market after receiving FDA approval of RYTELO™ (imetelstat) for treatment of adult patients with Lower-Risk MDS with Transfusion-Dependent Anemia  BCDA - Up over 45% in pre after announcing it has received a United States patent issuance on intramyocardial delivery of cell aggregates to the heart including minimally invasive radial artery approach VERO - Up over 100% in pre after announcing it had regained NASDAQ compliance SPOTLIGHT💡 *together with Mode Mobile Exclusive for Raging Bull Members: Get in By TONIGHT before the Price Jumps from $.16/share to $.25/share in the upcoming Reg A. [See Jeff’s interview with Mode’s CEO here]( to grasp how the company is transforming Smartphones into “Earned Phones.” “We’re basically the closest company to make smart phones for free… or better… to where it actually becomes an income stream.” – CEO Dan Novaes Over 21K shareholders participated in previously [sold-out]( allocations for Deloitte’s #1 ranked fastest software company 🦄. Fortunately, there is still time for RB members to get in – and even lock in 160% bonus shares! 📈 [Click Here to Get up to 160% Bonus Shares By June 10th*]( Disclosure: Please read the offering circular at [invest.modemobile.com](. HOTLIST🔥 GERN - Up over 38% in the pre market after receiving FDA approval of RYTELO™ (imetelstat) for treatment of adult patients with Lower-Risk MDS with Transfusion-Dependent Anemia  Geron Corporation (GERN) is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. Overnight, the [company announced]( that it had received FDA approval of RYTELO™ (imetelstat) for treatment of adult patients with Lower-Risk MDS with Transfusion-Dependent Anemia. Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life. "With the approval and availability of RYTELO, we believe eligible patients with lower-risk MDS can potentially experience meaningful clinical benefit, particularly the potential for greater than 24 weeks of freedom from the burden of red blood cell transfusions and symptomatic anemia," said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. The stock traded up over 38% in the pre-market in reaction to the news. The $5 area has acted as resistance in the pre-market and will be an important level to watch. Above it, targets to the upside are $5.20, $5.30, $5.56 and then the pre-market high at $6.14. Beyond that, $6.50, $7 and $7.50 come into play. Below $5, targets to the downside are $4.50, $4 and then a gap fill at $3.89. BCDA - Up over 45% in pre after announcing it has received a United States patent issuance on intramyocardial delivery of cell aggregates to the heart including minimally invasive radial artery approach BioCardia Inc. (BCDA) is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. In the pre-market this morning the [company announced]( it had received a United States patent issuance on intramyocardial delivery of cell aggregates to the heart including minimally invasive radial artery approach. The Unites States Patent Office has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a patent term that will expire in 2036. The present invention relates to medical methods and systems suitable for substance delivery to the heart via a radial artery and for the intracardiac delivery of cellular aggregates and other agglomerated materials. The stock traded up over 45% in the pre-market in reaction to the announcement. $5.95 acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $6.70, $7 and then the pre-market high at $7.41. Beyond that, $8, $8.85 and $10 come into play. Below $5.95, targets to the downside are $5.67, $5.20, $4.60 and then a gap fill at $4.37. VERO - Up over 100% in pre after announcing it had regained NASDAQ compliance Venus Concept Inc. (VERO) is a medical technology company that develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. In the after-hours yesterday, the [company announced]( that it had regained NASDAQ compliance. The Nasdaq Staff originally issued the Company a deficiency notice on May 31, 2023, citing that stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing. On May 28, 2024, the Company completed a $35 million debt-to-equity transaction. As confirmed by the Nasdaq’s notice dated June 4, 2024, this transaction served to bring the Company into compliance with the Minimum Equity Requirement. The stock traded up over 100% in the pre-market in reaction to the news. The $1.20 area acted as support in the after-hours and pre-market and will be an important level to watch. Above it, targets to the upside are $1.40, $1.60, $1.80, $2 and then the pre-market high at $2.15. Below $1.20, targets to the downside are $1, $0.80 and then a gap fill at $0.5867. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( *If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America